LLY

998.88

-0.19%↓

JNJ

243.11

-0.23%↓

ABBV

227.62

+0.42%↑

NVS

155.44

-3.77%↓

AZN

192.99

-1.1%↓

LLY

998.88

-0.19%↓

JNJ

243.11

-0.23%↓

ABBV

227.62

+0.42%↑

NVS

155.44

-3.77%↓

AZN

192.99

-1.1%↓

LLY

998.88

-0.19%↓

JNJ

243.11

-0.23%↓

ABBV

227.62

+0.42%↑

NVS

155.44

-3.77%↓

AZN

192.99

-1.1%↓

LLY

998.88

-0.19%↓

JNJ

243.11

-0.23%↓

ABBV

227.62

+0.42%↑

NVS

155.44

-3.77%↓

AZN

192.99

-1.1%↓

LLY

998.88

-0.19%↓

JNJ

243.11

-0.23%↓

ABBV

227.62

+0.42%↑

NVS

155.44

-3.77%↓

AZN

192.99

-1.1%↓

Kodu・Aktsiate loetelu・Mirati Therapeutics Inc

Mirati Therapeutics Inc

Suletud

SektorTervishoid

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

Max

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	-0.05% downside

Uudiste sentiment

By Acuity

50%

147 / 351 Pingereas Healthcare

Mirati Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

11. märts 2026, 19:18 UTC

Suurimad hinnamuutused turgudel

Stryker Shares Down After Cyberattack Tied to Iran-Linked Group

11. märts 2026, 23:54 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

11. märts 2026, 23:54 UTC

Market Talk

Nikkei May Decline on Energy Costs Concerns -- Market Talk

11. märts 2026, 23:51 UTC

Market Talk

Gold Falls as Rising Oil Prices Spur Inflation Worries -- Market Talk

11. märts 2026, 23:41 UTC

Market Talk

REA Bull Sees Potential Upside to Yield Guidance -- Market Talk

11. märts 2026, 23:37 UTC

Market Talk

Uudisväärsed sündmused

Oil Futures Rise Amid Ongoing Middle East Conflict -- Market Talk

11. märts 2026, 23:17 UTC

Uudisväärsed sündmused

Front-Month WTI Crude Oil Futures Rise 5.5% to $92.05/bbl

11. märts 2026, 23:17 UTC

Uudisväärsed sündmused

Front-Month Crude Oil Futures Rise Amid Ongoing Middle East Conflict

11. märts 2026, 22:29 UTC

Market Talk

Australia Shares Set to Fall in Early Trade -- Market Talk

11. märts 2026, 21:47 UTC

Tulu

Liontown Resources: Market Tailwinds Strengthening Outlook

11. märts 2026, 21:46 UTC

Tulu

Liontown Resources: 4 Mln Ton Per Annum Expansion Study Underway

11. märts 2026, 21:45 UTC

Tulu

Liontown Resources Says FY26 Guidance Unchanged

11. märts 2026, 21:45 UTC

Tulu

Liontown Resources 1H Unit Operating Costs A$985/Ton

11. märts 2026, 21:44 UTC

Tulu

Liontown Resources 1H Underlying Ebitda Loss A$7.7 Million

11. märts 2026, 21:43 UTC

Tulu

Liontown Resources 1H Revenue A$207.5 Million

11. märts 2026, 21:43 UTC

Tulu

Liontown Resources 1H Net Loss A$184 Million

11. märts 2026, 21:12 UTC

Omandamised, ülevõtmised, äriostud

Netflix Rival Strikes Deal With Google in Battle for AI Content -- Barrons.com

11. märts 2026, 21:10 UTC

Tulu

Vista Gold FY25 Loss $7.5M >VGZ

11. märts 2026, 21:10 UTC

Tulu

Vista Gold FY25 Loss/Shr 6c >VGZ

11. märts 2026, 20:50 UTC

Market Talk

Uudisväärsed sündmused

Basic Materials Roundup: Market Talk

11. märts 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

11. märts 2026, 20:27 UTC

Omandamised, ülevõtmised, äriostud

Papa John's Draws Fresh Takeover Interest -- 2nd Update

11. märts 2026, 20:26 UTC

Tulu

These Stocks Are Today's Movers: Oracle, UniFirst, Fair Isaac, Nebius, AeroVironment, Campbell's, and More -- Barrons.com

11. märts 2026, 20:19 UTC

Uudisväärsed sündmused

The Strait of Hormuz Could Take Weeks -- Even Months -- to Reopen, Military Experts Say -- Barrons.com

11. märts 2026, 20:15 UTC

Tulu

This Physical AI Stock Jumped on Earnings. The Robots Are Coming. -- Barrons.com

11. märts 2026, 20:12 UTC

Uudisväärsed sündmused

Stock Market Today: Oil Prices Push Higher Despite IEA Oil Release Headline -- WSJ

11. märts 2026, 19:31 UTC

Market Talk

Uudisväärsed sündmused

Oil Futures Gain Despite IEA's Planned Release of Reserves -- Market Talk

11. märts 2026, 19:01 UTC

Market Talk

Uudisväärsed sündmused

U.S. Natural Gas Gains With Middle East Conflict in View -- Market Talk

11. märts 2026, 18:59 UTC

Omandamised, ülevõtmised, äriostud

Berkshire's Deal for Occidental Chemicals Unit Is a Winner as Chemical Stocks Surge -- Barrons.com

11. märts 2026, 18:43 UTC

Uudisväärsed sündmused

Chubb Named Lead Insurer for U.S. Plan to Protect Oil Tankers in Strait of Hormuz -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Mirati Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

-0.05% langus

12 kuu keskmine prognoos

Keskmine 58.67 USD -0.05%

Kõrge 59 USD

Madal 58 USD

Põhineb 5 Wall Streeti analüütiku instrumendi Mirati Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

5 ratings

Osta

Hoia

Müü

Põhineb 5 analüütiku instrumendi Mirati Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

147 / 351 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

EBITDA

Ärikasum

Ettevõttest Mirati Therapeutics Inc

Mirati Therapeutics, Inc. is a clinical-stage oncology company. It is focused on developing therapeutics to address the genetic and immunological promoters of cancer. Its clinical programs consist of product candidates, including Adagrasib (MRTX849), MRTX1133, and Sitravatinib. MRTX849 is an oral small-molecule therapy designed to shrink difficult-to-treat cancers harboring the KRAS G12C mutation. MRTX1133 is a small molecule-inhibitor of the KRASG12D mutation, designed to treat patients with unmet need. Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor that can stimulate the body’s immune response to fight cancer. MRTX849 is in Phase III and Phase I/II clinical trials and MRTX1133 is in preclinical development. Sitravatinib is in a Phase III clinical trial, and Phase I/II clinical trials. It also has additional preclinical discovery programs, which includes first-in-class and best-in-class product candidates designed to address mutations and tumors.